6-Butyl-3-cyano-2-pyridone | 118420-86-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-Butyl-3-cyano-2-pyridone
• 英文别名: 6-Butyl-3-cyano-2(1H)-pyridinone；6-butyl-3-cyano-1,2-dihydro-2-oxopyridine；6-Butyl-2-oxo-1,2-dihydropyridine-3-carbonitrile；6-butyl-2-oxo-1H-pyridine-3-carbonitrile
• CAS: 118420-86-3
• 化学式: C₁₀H₁₂N₂O
• 分子量: 176.218
• InChiKey: GKHPDWUKQJHOBM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-Butyl-3-cyano-2-pyridone 在 palladium on activated charcoal sodium hydroxide 、 叠氮磷酸二苯酯 、 氢溴酸 、 氢气 、 sodium hydride 、 溶剂黄146 、 三乙胺 作用下， 生成 (3-Amino-6-butyl-2-oxo-2H-pyridin-1-yl)-acetic acid tert-butyl ester
  参考文献：
  名称：

  PYRIDONE-BASED PEPTIDOMIMETIC INHIBITORS OF INTERLEUKIN-1β-CONVERTING ENZYME (ICE)

  摘要：

  New potent, reversible inhibitors of recombinant human Interleukin-1 beta-converting enzyme (ICE, caspase-1) with significantly reduced peptide character are described. The compounds were designed by incorporation of pyridone and pyrimidone heterocyclic replacements for the P-2-P-3 amino acids of the native substrate and were optimised by manipulation of peripheral alkyl and aryl substituents. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00220-5
• 作为产物：
  描述：

  正溴丁烷 、 3-氰基-6-甲基-2(1H)-吡啶酮 在 正丁基锂 、 二异丙胺 作用下， 以 四氢呋喃 、 hexanes 为溶剂， 反应 3.25h， 以61%的产率得到6-Butyl-3-cyano-2-pyridone
  参考文献：
  名称：

  Asymmetric conjugate addition reaction

  摘要：

  这项发明涉及一种内皮素拮抗剂合成中的关键中间体，通过不对称共轭加成反应合成这种关键中间体。

  公开号：

  US06353110B1

文献信息

• Dual-acting antihypertensive agents
  申请人：Allegretti Paul

  公开号：US20080269305A1

  公开（公告）日：2008-10-30

  The invention is directed to compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R 5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  该发明涉及具有以下公式的化合物：其中：Ar、r、Y、Z、Q、W、X和R5-7如规范中定义，并且其药学上可接受的盐。这些化合物具有AT1受体拮抗活性和神经肽酶抑制活性。该发明还涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• On the regiochemistry of the alkylation of tert-butyl N-[6-butyl-1,2-dihydro-2-oxo-3-pyridylmethyl]carbamate: Precursor of a series of potent angiotensin II receptor antagonists
  作者：Thomas Koppe、Werner W.K.R. Mederski、Mathias Osswald、Michael Schwarz

  DOI：10.1016/0040-4039(94)02306-v

  日期：1995.1

  The key intermediate 5 of a large number of potent AT1 selective angiotensin II antagonists e.g. the potent cyclopropylmethyl derivative 1 (EMD 69943) was synthesized by regioselective alkylation of carbamate 3 with the well-known 4′-(bromomethyl)biphenyl-2-carbonitrile (4) and n-butyllithium as the preferred base.

  大量有效的AT 1选择性血管紧张素II拮抗剂（例如有效的环丙基甲基衍生物1（EMD 69943））的关键中间体5是通过氨基甲酸3的区域选择性烷基化与众所周知的4'-（溴甲基）联苯-2-甲腈合成的（4）和正丁基锂为优选的碱。
• Substituted pyridinones and pyrimidinones as angiotensin II antagonists
  申请人：FISONS plc

  公开号：EP0500297A1

  公开（公告）日：1992-08-26

  There are described substituted heterocycles of general formula I, which are useful as angiotensin II antagonists there are also described methods for making the compounds and pharmaceutical formulations, eg for the treatment of hypertension, comprising them.

  已描述了一般式I的替代杂环化合物，这些化合物可用作抗血管紧张素II受体拮抗剂，还描述了制备这些化合物和药物配方的方法，例如用于治疗高血压。
• Dual-acting Imidazole antihypertensive agents
  申请人：Allegretti Paul

  公开号：US20090023228A1

  公开（公告）日：2009-01-22

  The invention is directed to compounds having the formula: wherein: Ar, r, R 2-3 , X, and R 5.7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  本发明涉及具有以下结构式的化合物：其中：Ar、r、R2-3、X和R5.7如规范中所定义，并且其药学上可接受的盐。这些化合物具有AT1受体拮抗活性和神经肽酶抑制活性。本发明还涉及包含这些化合物的制药组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• Dual-acting imidazole antihypertensive agents
  申请人：Theravance, Inc.

  公开号：US08158659B2

  公开（公告）日：2012-04-17

  The invention is directed to compounds having the formula: wherein: Ar, r, R2-3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  本发明涉及具有以下式子的化合物：其中：Ar、r、R2-3、X和R5-7的定义如规范所述，以及其药学上可接受的盐。这些化合物具有AT1受体拮抗活性和肽酶抑制活性。本发明还涉及包含这些化合物的制药组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。